In Vivo Alzheimer Proteomics

NCT02263235 | Terminated

• 1 other identifier: 8652
• Study Type: interventional
• Target: 89
• Locations: 1 country
• Sites: 1

Brief Summary

In France, an estimated 860 000 patients are affected by Alzheimer Disease (AD) which represents, as in other developed countries, a major public health issue. In many cases, AD diagnosis is uncertain and its clinical evolution unpredictable. The exactitude of the diagnosis is however particularly important in the perspective of the validation and use of new therapeutic strategies in AD. Detection of cerebrospinal fluid (CSF) diagnosis biomarkers fell short in the detection, of atypical/mixed cases, of some differential diagnosis, and in differentiating rapid or slow clinical evolutions. Hence, CSF analysis gives a unique opportunity to detect and validate biomarkers in many neurological disorders. Nevertheless, in medical practice, CSF biological analysis is currently limited to a small number of analytes.Quantitative and targeted mass spectrometry, especially operated in the Multiple reaction monitoring mode (MRM), represents an alternative to immunodetection and could be used to detect specific biomarkers in complex matrices such as plasma by specifically discriminating the proteotypic peptides corresponding to each proteins. Mass spectrometry has also the ability to distinguish and quantify isotopically labelled and unlabeled selected targets. This ability was used in a publication by the group of R. Bateman (Washington University, St Louis, USA) who could, after administering stable isotope-labelled leucine, evaluate Ab synthesis and clearance in humans. This approach has an enormous potential to study the metabolism of proteins within the human CNS and consequently help in the understanding and diagnosis of neurological disorders.The main objective of this program is set up a targeted quantitative mass spectrometry method for existing and stable isotope-labelled CSF biomarkers in the neurological field; exploit this approach for diagnostic purpurses and to gain knowledge in the pathophysiology of diseases.

Conditions

Probable Alzheimer Disease; Parkinson Disease; Neurological Disease Without Cognitive Degradation; Brain Trauma; Acute Hydrocephaly

Keywords

Alzheimer disease (AD); diagnosis biomarkers; cerebrospinal fluid (CSF); targeted quantitative proteomics; mass spectrometry; stable isotope-labelled leucine

Outcome Measures

Primary Outcomes (2)

• C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at different time points (in %)

  Analysis of labelled samples with mass spectrometry. Data generated will be studied to validate the experimental model and understand the pathophysiology of neurological disorders. A collection of labelled biological samples will also be generated.

  1.5 years

• C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)

  C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)

  1.5 years

Study Arms (3)

Group 1

EXPERIMENTAL

60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)

Other: collection of CSF, blood, urine, saliva

Group 2A

EXPERIMENTAL

20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF

Biological: administration of stable isotope-labelled leucine-

Group 2B

EXPERIMENTAL

30 patients (15 probable AD, 15 neurological disease without cognitive degradation)

Biological: administration of stable isotope-labelled leucine-

Interventions

administration of stable isotope-labelled leucine- BIOLOGICAL

\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours

Group 2A; Group 2B

collection of CSF, blood, urine, saliva OTHER

\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours

Group 1

Eligibility Criteria

• Age: 55 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Reports written consent, informed and signed by the patient and a trusted person
• Subject member or beneficiary of a social security system
• Specific criteria for group 1 and 2B :
• Age between 55 and 85 years old for patients
• Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia with Lewy bodies, Parkinson disease)
• Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture (PL)
• Specific criteria for group 2A :
• \- Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute hydrocephaly) and favorable evolution that allows removal of the shunt

You may not qualify if:

• Patient deprived of liberty by judicial or administrative decision
• Major protected by law
• Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding
• Presence of a transmissible viral disease (HlV, hepatitis B and C)
• Patient included in a clinical trial
• lnadequate cardiac, hepatic or severe renal disfunction
• Disease amino acid metabolism (Leucinose..)
• Information clinical and para-clinical insufficient or unavailable
• Patient deprived of liberty by judicial or administrative decision
• Major protected by law
• Pregnancy, women of childbearing age with risk of pregnancy, or breast
• feeding
• Presence of a transmissible viral disease (HIV, hepatitis B and C)
• Patient included in a clinical trial
• Inadequate cardiac, hepatic or severe renal

Sponsors & Collaborators

• University Hospital, Montpellier: lead
• Assistance Publique - Hôpitaux de Paris: collaborator
• University Hospital, Clermont-Ferrand: collaborator
• International Atomic Energy Agency: collaborator

Study Sites (1)

Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Parkinson Disease; Brain Injuries, Traumatic; Alzheimer Disease

Interventions

Blood Specimen Collection; Urination

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Wounds and Injuries; Dementia; Tauopathies; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; Urinary Tract Physiological Phenomena; Reproductive and Urinary Physiological Phenomena

Study Officials

• Sylvain Lehmann, PU-PH

  Laboratoire de Biochimie et Protéomique Clinique, IRMB St Eloi, CHRU de Montpellier

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2014
• First Posted: October 13, 2014
• Study Start: October 8, 2013
• Primary Completion: May 22, 2018
• Study Completion: May 22, 2018
• Last Updated: December 28, 2021

Record last verified: 2021-12

Locations

FR (1)